PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB決算レポート

Nasdaq · biotechnology industry

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

PACB Q4 2025 Key Financial Metrics

売上高

$44.6M

粗利益

$16.6M

営業利益

$-41.2M

純利益

$-40.4M

粗利益率

37.1%

営業利益率

-92.3%

純利益率

-90.4%

前年比成長

13.8%

EPS

$-0.11

資金フロー

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Q4 2025 財務サマリー

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported revenue of $44.6M (up 13.8% YoY) for Q4 2025, with a net profit of $-40.4M (down 1802.7% YoY) (-90.4% margin). Cost of goods sold was $28.1M, operating expenses totaled $57.8M.

主要財務指標

総売上高$44.6M
純利益$-40.4M
粗利益率37.1%
営業利益率-92.3%
報告期間Q4 2025

売上内訳

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Q4 2025 revenue of $44.6M breaks down across 2 segments, led by Products at $39.0M (87.3% of total).

セグメント売上高構成比
Products$39.0M87.3%
Service And Other$5.7M12.7%

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. セグメント別売上 — 四半期推移

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and Service And Other) has evolved quarter over quarter.

セグメントQ4 2025Q3 2025Q2 2025Q1 2025
Products$39.0M$32.6M$33.1M$31.1M
Service And Other$5.7M$5.8M$6.7M$6.0M

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 年度売上推移

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $160.0M). Click any linked year to see what changed vs the prior 10-K.

年度年間売上
2025$160.0Mvs 2024
2024$154.0Mvs 2023
2022$128.3M

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 四半期売上・純利益の履歴

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.

四半期売上高売上前年比純利益純利益率
Q4 2025$44.6M+13.8%$-40.4M-90.4%
Q3 2025$38.4M-3.8%$-38.0M-98.9%
Q2 2025$39.8M+10.4%$-41.9M-105.4%
Q1 2025$37.2M-4.3%$-426.1M-1146.8%
Q4 2024$39.2M$2.4M6.0%
Q3 2024$40.0M-28.2%$-60.7M-151.9%
Q2 2024$36.0M-24.3%$-173.3M-481.3%
Q1 2024$38.8M-0.2%$-78.2M-201.4%

損益計算書

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
売上高$38.8M$36.0M$40.0M$39.2M$37.2M$39.8M$38.4M$44.6M
前年比成長-0.2%-24.3%-28.2%N/A-4.3%10.4%-3.8%13.8%

貸借対照表

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
総資産$1.67B$1.51B$1.45B$1.26B$860.8M$825.5M$803.2M$784.1M
総負債$1.02B$1.02B$996.9M$753.9M$769.2M$764.0M$767.1M$778.7M
株主資本$649.0M$492.7M$453.1M$506.6M$91.6M$61.5M$36.1M$5.3M

キャッシュフロー

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
営業CF$-75.7M$-54.3M$-45.5M$-30.6M$-44.1M$-29.4M$-18.7M$-19.1M